Dental and Medical Problems
2015, vol. 52, nr 1, January-March, p. 22–25
Publication type: original article
Relationship Between Salivary and Plasma Level of Homocysteine in Coronary Artery Disease
Związek między ślinowym i osoczowym stężeniem homocysteiny w chorobie wieńcowej serca
1 Department of Oral Medicine, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Modaress Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Private practioner, Tehran, Iran
Background. It is believed that an elevated plasma homocysteine concentration conferred an independent risk of cardiovascular disease and plasma homocystine level can predict the mortality rate of patients suffering from cardiac disease.
Objectives. We designed this study to evaluate the relationship between salivary and plasma level of homocysteine in cardiovascular patients and control group.
Material and Methods. We obtained 5 mL blood and 2.5 mL saliva from 34 patients with coronary artery diseases (CAD) and 32 healthy individuals and detected homocysteine in their blood and saliva by high pressure liquid chromatography (HPLC) method. The difference between homocysteine level of patient and control group was compared with t-test. In addition, Pearson-coefficient was also used to determine the relationship between salivary and plasma level of homocysteine.
Results. The average of plasma homocysteine level was 15.43 ± 5.07 mmol/Lit in patients and 9.95 ± 5.88 mmol/ /Lit in the control group; their difference was statistically significant when compared with the use of Student t-test (p < 0.001). The average of salivary homocysteine level was 0.24 ± 0.056 mmol/Lit in patients and 0.023 ± 0.013 mmol/ /Lit in the control group; their difference was statistically significant (p < 0.001) with the use of Student t-test. There was a relationship between saliva and plasma level of homocysteine in both groups (Person-coefficient = 0.744)
Conclusion. There was a relationship between saliva and plasma level of homocysteine, so it can be used as an alternative media for detecting and measuring homocysteine.
coronary heart disease, saliva, homocystein
choroba wieńcowa serca, ślina, homocysteina
- Fortin L.J., Genest J. Jr.: Measurement of homocyst(e)ine in the prediction of arteriosclerosis. Clin. Biochem. 1995, 28, 155–162.
- Humphrey L.L., Fu R., Rogers K., Freeman M., Helfand M.: Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin. Proc. 2008, 83, 1203–1212.
- Jarosz A., Nowicka G.: C-reactive protein and homocysteine as risk factors of atherosclerosis. Przegl. Lek. 2008, 65, 268–272.
- Rudzite V., Fuchs D., Kalnins U., Jurika E., Silava A., Erglis A.: Prognostic value of tryptophan load test followed by serum kynurenine determination. Its comparison with pyridoxal-5-phosphate, kynurenine, homocysteine and neopterin amounts. Adv. Exp. Med. Biol. 2003, 527, 307–315.
- Welch G.N., Loscalzo J.: Homocysteine and atherothrombosis. N. Engl. J. Med. 1998, 338, 1042–1050.
- Foley J.D., Sneed J.D., Steinhubl S.R., Kolasa J., Ebersole J.L., Lin Y.: Oral fluids that detect cardiovascular disease biomarkers. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012, 114, 207–214.
- Pink R., Simek J., Vondrakova J., Faber E., Michl P., Pazdera J.: Saliva as a diagnostic medium. Biomed Pap. Med. Fac. Univ Palacky Olomouc Czech Repub. 2009, 153,103–110.
- Dillon M.C., Opris D.C., Kopanczyk R., Lickliter J., Cornwell H.N., Bridges E.G.: Detection of homocystiene and c-reactive protein in the saliva of healthy adults: comprasion with blood levels. Biomark Insights 2010, 5, 57–61.
- Boulot-Tolle M., Chadefaux B., Kamoun P.: Salivary homocyst(e)ine concentrations. Clin Chem. 1992, 38, 1504–1505.
- Bald E., Głowacki R.: Analysis of saliva for glutathione and metabolically related thiols by liquid chromatography with ultraviolet detection. Amino Acids 2005, 28, 431–433.
- Cummings D.M., King D.E., Mainous A.G., Geesey M.E.: Combining serum biomarkers: the association of C-reactive protein, insulin sensitivity, and homocysteine with cardiovascular disease history in the general US population. Eur. J. Cardiovasc. Prev. Rehabil. 2006, 13, 180–185.
- Wilson P.W., Pencina M., Jacques P., Selhub J., D’Agostino R. Sr., O’Donnell C.J.: C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ. Cardiovasc. Qual. Outcom. 2008, 1, 92–97.